Sphingosine kinase 2 supports the development of BCR/ABL-independent acute lymphoblastic leukemia in mice

dc.contributor.author Xie, Vicki
dc.contributor.author Tong, Daochen
dc.contributor.author Wallington-Beddoe, Craig T
dc.contributor.author Bradstock, Kenneth F
dc.contributor.author Bendall, Linda J
dc.date.accessioned 2018-02-19T05:15:18Z
dc.date.available 2018-02-19T05:15:18Z
dc.date.issued 2018-02-05
dc.date.updated 2018-02-15T06:51:46Z
dc.description © The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated
dc.description.abstract Background Sphingosine kinase (SphK) 2 has been implicated in the development of a range of cancers and inhibitors of this enzyme are currently in clinical trial. We have previously demonstrated a role for SphK2 in the development of acute lymphoblastic leukemia (ALL). Methods In this and our previous study we use mouse models: in the previous study the disease was driven by the proto-oncogene BCR/ABL1, while in this study cancer risk was elevated by deletion of the tumor suppressor ARF. Results Mice lacking ARF and SphK2 had a significantly reduced incidence of ALL compared mice with wild type SphK2. Conclusions These results show that the role of SphK2 in ALL development is not limited to BCR/ABL1 driven disease extending the potential use of inhibitors of this enzyme to ALL patients whose disease have driver mutations other than BCR/ABL1."
dc.identifier.citation Xie, V., Tong, D., Wallington-Beddoe, C. T., Bradstock, K. F., & Bendall, L. J. (2018). Sphingosine kinase 2 supports the development of BCR/ABL-independent acute lymphoblastic leukemia in mice. Biomarker Research, 6(1). https://doi.org/10.1186/s40364-018-0120-4
dc.identifier.doi https://doi.org/10.1186/s40364-018-0120-4
dc.identifier.uri https://doi.org/10.1186/s40364-018-0120-4
dc.identifier.uri http://hdl.handle.net/2328/37757
dc.language.iso en en
dc.publisher BioMed Central
dc.rights © The Author(s) 2018
dc.rights.holder The Author(s)
dc.rights.license CC-BY
dc.subject Acute lymphoblastic leukemia
dc.subject Sphingosine kinase 2
dc.subject Mouse models
dc.title Sphingosine kinase 2 supports the development of BCR/ABL-independent acute lymphoblastic leukemia in mice
dc.type Article en
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
40364_2018_Article_120.pdf
Size:
2.4 MB
Format:
Adobe Portable Document Format
Description:
Publisher version
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.84 KB
Format:
Item-specific license agreed upon to submission
Description: